| Variable | Active user group | Passive user group | p Value | ||
|---|---|---|---|---|---|
| (n = 508) | (n = 316) | ||||
| Age distribution | 20s | 1 (0.2) | 0 (0.0) | 0.047 | |
| 30s | 10 (2.0) | 3 (0.9) | |||
| 40s | 36 (7.1) | 20 (6.3) | |||
| 50s | 127 (25.0)* | 58 (18.4)* | |||
| 60s | 205 (40.4) | 126 (39.9) | |||
| 70 years and older | 129 (25.4)* | 108 (34.2)* | |||
| No answer | 0 (0.0) | 1 (0.3) | |||
| Workplace | Type | Clinic | 422 (83.0) | 259 (81.9) | 0.15 |
| Hospital | 85 (16.8) | 55 (17.4) | |||
| No answer | 1 (0.2) | 2 (0.6) | |||
| Region in Japan | Hokkaido/Tohoku | 48 (9.5) | 14 (5.1) | 0.10 | |
| Kanto | 154 (30.7) | 79 (25.2) | |||
| Chubu/Hokuriku | 69 (14.1) | 53 (16.9) | |||
| Kinki | 85 (17.4) | 62 (20.1) | |||
| Chugoku/Shikoku | 65 (13.5) | 44 (14.3) | |||
| Kyushu/Okinawa | 65 (13.1) | 47 (15.6) | |||
| No answer | 9 (1.8) | 9 (2.9) | |||
| History of nephrology training | Yes | 134 (26.4)* | 63 (19.9)* | 0.01 | |
| No | 374 (73.6) | 250 (79.1) | |||
| No answer | 0 (0.0) | 3 (0.9) | |||
| Specialty | Internal medicine | 426 (83.9) | 276 (87.3) | 0.17 | |
| Cardiology | 113 (22.2) | 39 (12.3) | <0.001 | ||
| Diabetology and metabolism | 93 (18.3) | 43 (13.6) | 0.08 | ||
| Gastroenterology | 96 (18.9) | 63 (19.9) | 0.71 | ||
| Pulmonology | 41 (8.1) | 18 (5.7) | 0.20 | ||
| Neurology | 14 (2.8) | 15 (4.7) | 0.13 | ||
| Hematology | 12 (2.4) | 7 (2.2) | 0.89 | ||
| Rheumatology | 12 (2.4) | 10 (3.2) | 0.49 | ||
| Allergy | 22 (4.3) | 5 (1.6) | 0.03 | ||
| Psychiatry | 7 (1.4) | 6 (1.9) | 0.56 | ||
| Other | 17 (3.3) | 17 (5.4) | 015 | ||
| Active user group | Passive user group | p Value† | ||
|---|---|---|---|---|
| (n = 508) | (n = 316) | |||
| Q1 | Do you possess the CKD guidelines 2023? | |||
| Yes, and I use them frequently. | 121 (23.8)# | 52 (16.5)# | 0.02 | |
| Yes, but I have not used them. | 175 (34.4) | 106 (33.5) | ||
| No, but I would like to obtain the CKD Guidelines 2024 for GPs. | 176 (34.6) | 121 (38.3) | ||
| I do not possess them and do not wish to obtain the CKD Guidelines 2024 for GPs. | 32 (6.3)* | 35 (11.1)* | ||
| No answer. | 4 (0.8) | 2 (0.6) | ||
| Q2* | What parameters do you use to assess kidney function? | |||
| Serum creatinine level. | 291 (57.3) | 203 (64.2) | 0.048 | |
| eGFRcreatinine level. | 491 (96.7) | 289 (91.5) | 0.001 | |
| Serum cystatin C level. | 74 (14.6) | 33 (10.3) | 0.09 | |
| eGFRcystatinC level. | 81 (15.9) | 24 (7.6) | < 0.001 | |
| Creatinine clearance (24-h urine collection). | 12 (2.4) | 9 (1.9) | 0.66 | |
| Q3 | How do you diagnose patients as having CKD? | |||
| Only by urine test. | 2 (0.4)# | 6 (1.9)# | < 0.001 | |
| Only by eGFR level. | 29 (5.7)# | 41 (13.0)# | ||
| By both urine test and eGFR level. | 370 (72.8) | 234 (74.1) | ||
| By urine test, eGFR level, and kidney imaging. | 104 (20.5)# | 33 (10.4)# | ||
| No answer | 3 (0.6) | 2 (0.6) | ||
| Q4 | Do you check urine tests for patients with CKD during regular visits? | |||
| Perform quantitative tests for proteinuria (g/gCr). | 203 (40.0)# | 170 (53.8)# | < 0.001 | |
| Perform only qualitative tests for proteinuria. | 205 (40.4)# | 84 (26.6)# | ||
| Do not perform urine testing. | 10 (2.0) | 11 (3.5) | ||
| No answer | 90 (17.7) | 51 (16.1) | ||
| Q5 | Do you check albuminuria in patients with diabetes during regular visits? | |||
| Quantitative tests every 3 months. | 102 (20.1)# | 40 (12.7)# | < 0.001 | |
| Quantitative tests once or twice a year. | 216 (42.5)# | 76 (24.1)# | ||
| Rarely perform quantitative tests. | 75 (14.8)# | 69 (21.8)# | ||
| Perform only qualitative tests. | 32 (6.3) | 30 (9.5) | ||
| Do not check albuminuria. | 82 (16.1)# | 100 (31.6)# | ||
| No answer | 1 (0.2%) | 1 (0.3) | ||
| Q6 | Do you evaluate BP in patients with CKD during clinic visits? | |||
| I evaluate both office BP and home BP in the early morning. | 444 (87.4)# | 259 (82.0)# | 0.01 | |
| I evaluate only home BP in the early morning. | 27 (5.3) | 14 (4.4) | ||
| I evaluate only office BP. | 36 (7.1)# | 38 (12.0)# | ||
| I do not evaluate either. | 0 (0.0)# | 5 (1.6)# | ||
| No answer | 1 (0.2) | 0 (0.0) | ||
| Q7 | Do you prescribe RAS inhibitors to patients with CKD and hypertension? | |||
| I prescribe them as first-line medication. | 393 (77.4)# | 222 (70.3)# | < 0.001 | |
| I prescribe them to patients with proteinuria. | 93 (18.3) | 54 (17.1) | ||
| I rarely prescribe them. | 20 (3.9)# | 39 (12.3)# | ||
| No answer | 2 (0.4) | 1 (0.3) | ||
| Q8* | When do you discontinue RAS inhibitors in patients with CKD? | |||
| When kidney function deteriorates. | 178 (35.3) | 125 (39.8) | 0.20 | |
| When the serum Cr level reaches 2 mg/dL. | 122 (24.2) | 72 (22.9) | 0.68 | |
| When the serum potassium level exceeds the normal range. | 225 (44.6) | 152 (48.4) | 0.29 | |
| I continue prescribing them for their renoprotective effects. | 245 (48.6) | 127 (40.4) | 0.02 | |
| I do not prescribe them to patients with CKD. | 7 (1.4) | 16 (5.1) | 0.002 | |
| Q9* | How do you evaluate salt intake in patients with CKD? | |||
| By Tanaka’s formula using spot urine samples. | 198 (40.1) | 74 (24.3) | < 0.001 | |
| By direct measurement using 24-h urine collection. | 2 (0.4) | 6 (2.0) | 0.03 | |
| By patient interview. | 164 (33.2) | 114 (37.4) | 0.23 | |
| I do not evaluate salt intake by either method. | 143 (28.9) | 120 (39.3) | 0.002 | |
| Q10* | Which parameters do you use to evaluate renal anemia? | |||
| Hemoglobin level. | 500 (98.4) | 300 (95.2) | 0.007 | |
| Mean corpuscular volume (MCV). | 301 (59.3) | 144 (45.7) | < 0.001 | |
| Serum iron (Fe) level. | 362 (71.3) | 194 (61.6) | 0.004 | |
| Transferrin saturation (TSAT). | 162 (31.9) | 47 (14.9) | < 0.001 | |
| Serum ferritin level. | 362 (71.3) | 187 (59.4) | < 0.001 | |
| Serum erythropoietin level. | 232 (45.7) | 148 (47.0) | 0.71 | |
| Q11 | Do you prescribe erythropoiesis-stimulating agents to patients with CKD? | |||
| Yes, I prescribe them at my own discretion. | 347 (68.3)# | 165 (52.2)# | < 0.001 | |
| Yes, I prescribe them when recommended by a nephrologist. | 92 (18.1)# | 83 (26.3)# | ||
| No, I do not prescribe them. | 63 (12.4)# | 63 (19.9)# | ||
| No answer | 6 (1.2) | 5 (1.6) | ||
| Q12 | Do you prescribe HIF-PH inhibitors to patients with CKD? | |||
| Yes, I prescribe them at my own discretion. | 306 (60.2)# | 110 (34.8)# | < 0.001 | |
| Yes, I prescribe them when recommended by a nephrologist. | 102 (20.1) | 78 (24.7) | ||
| No, I do not prescribe them. | 87 (17.1)# | 118 (37.3)# | ||
| No answer | 13 (2.3) | 10 (3.2) | ||
| Q16 | How do you manage serum potassium levels in patients with CKD? | |||
| I regularly check potassium levels and manage hyperkalemia continuously. | 333 (65.6)# | 150 (47.5)# | < 0.001 | |
| I check potassium regularly but provide only temporary treatment. | 82 (16.1)# | 73 (23.1)# | ||
| I check potassium regularly but refer hyperkalemia management to a nephrologist. | 62 (12.2)# | 57 (18.0)# | ||
| I do not check potassium but manage hyperkalemia per nephrologist instructions. | 24 (4.7)# | 26 (8.2)# | ||
| I neither check nor treat hyperkalemia. | 7 (1.4) | 10 (3.2) | ||
| Q18 | Do you evaluate serum calcium and phosphorus levels in patients with CKD? | |||
| I regularly check both calcium and phosphorus levels. | 258 (50.8)# | 106 (33.5)# | < 0.001 | |
| I regularly check only calcium levels. | 119 (23.4) | 82 (25.9) | ||
| I check them only in patients on vitamin D therapy. | 65 (12.8) | 39 (12.3) | ||
| I do not check them but rely on nephrologists. | 45 (8.9)# | 63 (19.9)# | ||
| I never check them. | 16 (3.1)# | 26 (8.2)# | ||
| No answer | 5 (1.0) | 0 (0.0) | ||
| Q19 | Do you provide dietary therapy to patients with non–dialysis-dependent CKD? | |||
| I provide it at my clinic or hospital. | 345 (67.9)# | 159 (50.3)# | < 0.001 | |
| I refer patients to nephrologists for dietary therapy. | 107 (21.1)# | 96 (30.4)# | ||
| I neither provide nor refer for dietary therapy. | 53 (10.4)# | 61 (19.3)# | ||
| No answer | 3 (0.6) | 0 (0.0) | ||
| Q20* | What types of CKD dietary therapy do you provide? | |||
| Restriction of daily salt intake. | 479 (96.8) | 284 (94.0) | 0.06 | |
| Restriction of daily protein intake. | 322 (65.1) | 189 (62.6) | 0.48 | |
| Guidance on appropriate daily calorie intake. | 171 (34.5) | 89 (29.5) | 0.14 | |
| Restriction of daily phosphate intake. | 223 (45.1) | 97 (32.1) | < 0.001 |
| Active user group | Passive user group | p Value† | ||
|---|---|---|---|---|
| (n = 508) | (n = 316) | |||
| Q21 | Is CKD collaborative care between GPs and nephrologists active in your region? | |||
| Yes, fully active. | 128 (25.2) | 71 (22.5) | 0.64 | |
| Yes, partially active. | 234 (46.1) | 149 (47.2) | ||
| No, it does not work well. | 108 (21.3) | 64 (20.3) | ||
| No, and there is no CKD collaborative care between GPs and nephrologists. | 36 (7.1) | 31 (9.8) | ||
| No answer | 2 (0.4) | 1 (0.3) | ||
| Q22 | Do you know any nephrologists whom you can consult regarding patients with CKD? | |||
| Yes, I know several nephrologists available for consultation. | 385 (75.8) | 241 (67.3) | 0.09 | |
| Yes, I know only one nephrologist available for consultation. | 71 (14.0) | 31 (9.8) | ||
| No | 48 (9.4) | 43 (13.6) | ||
| No answer | 4 (0.8) | 1 (0.3) | ||
| Q23 | How is your relationship with nephrologists available for consultation? | |||
| I know them well personally. | 169 (33.3)# | 71 (22.5)# | 0.003 | |
| I know only their names. | 277 (54.5) | 190 (60.1) | ||
| I do not know them well. | 58 (11.4)# | 54 (17.1)# | ||
| No answer | 4 (0.8) | 1 (0.3) | ||
| Q24 | Do you use the referral criteria for CKD consultation recommended in the CKD Guidelines (Japanese Society of Nephrology)? | |||
| I use it often. | 86 (16.9) | 38 (12.0) | 0.004 | |
| I use it sometimes. | 230 (45.3)# | 120 (38.0)# | ||
| I rarely use them. | 100 (19.7) | 64 (20.3) | ||
| I know about them but do not use them. | 70 (13.8)# | 73 (23.1)# | ||
| I do not know about them. | 19 (3.7) | 19 (6.0) | ||
| No answer | 3 (0.6) | 2 (0.6) | ||
| Q25* | For which patients with CKD do you usually consult nephrologists? | |||
| With evident proteinuria (> 0.5 g/gCr) | 294 (59.6) | 187 (59.4) | 0.94 | |
| With both proteinuria and hematuria | 250 (50.7) | 117 (37.1) | < 0.001 | |
| With eGFR < 45 mL/min/1.73 m2 | 313 (63.5) | 218 (69.2) | 0.10 | |
| With rapid eGFR decline | 420 (85.2) | 264 (83.8) | 0.60 | |
| With worsening symptoms including edema | 208 (42.2) | 155 (49.2) | 0.05 | |
| With worsening control of blood pressure or glucose | 87 (17.6) | 72 (22.2) | 0.07 | |
| With need for dietary counseling | 128 (26.0) | 90 (28.6) | 0.42 | |
| With need for explanation of kidney replacement therapy or conservative kidney management | 313 (63.5) | 173 (54.9) | 0.02 | |
| Q28* | What CKD-related treatments would you like nephrologists to provide? | |||
| Salt reduction counseling | 192 (39.0) | 121 (37.7) | 0.92 | |
| CKD-specific dietary counseling | 326 (66.3) | 221 (70.6) | 0.20 | |
| Management of blood pressure | 124 (25.2) | 112 (35.8) | 0.001 | |
| Management of plasma glucose | 60 (12.2) | 58 (18.5) | 0.01 | |
| Treatment for renal anemia | 181 (36.8) | 149 (47.6) | 0.002 | |
| Treatment of electrolyte abnormalities or metabolic acidosis | 289 (58.7) | 188 (60.1) | 0.71 | |
| Explanation of kidney replacement therapy or conservative kidney management | 412 (83.7) | 265 (84.7) | 0.73 | |
| Q29 | Are you satisfied with nephrologists’ CKD consultation? | |||
| Completely satisfied | 129 (26.1) | 58 (18.4) | 0.11 | |
| Satisfied sometimes | 214 (43.2) | 150 (47.6) | ||
| Neither satisfied nor dissatisfied | 114 (23.0) | 84 (26.7) | ||
| Occasionally dissatisfied | 28 (5.7) | 18 (5.7) | ||
| Not satisfied at all | 6 (1.2) | 1 (0.3) | ||
| No answer | 4 (0.8) | 4 (1.3) | ||
| Q30* | Which aspects of the consultation were unsatisfactory? | |||
| Insufficient patient counseling or explanation | 60 (12.2) | 34 (10.9) | 0.57 | |
| Insufficient feedback to GPs | 83 (16.8) | 51 (16.3) | 0.84 | |
| Inadequate treatment (e.g., no change in medication) | 99 (20.1) | 59 (18.8) | 0.67 | |
| Insufficient counseling by nutritionists or pharmacists | 48 (9.7) | 31 (9.9) | 0.94 |
| Question | Answer | Reference group | p Value | Exp(B) | 95 % CI | |
|---|---|---|---|---|---|---|
| Specialty | Cardiology | Yes | No | 0.03 | 1.84 | [1.06-3.19] |
| Rheumatology | Yes | No | 0.042 | 0.28 | [0.08-0.96] | |
| Allergy | Yes | No | 0.005 | 6.13 | [1.74-21.56] | |
| Q2 | Use of serum cystatin C level to evaluate kidney function | Yes | No | 0.011 | 2.05 | [1.18-3.60] |
| Q3 | Diagnosis of CKD by both urine test and eGFR level | By both urine test and eGFR level | Only by urine test | 0.042 | 15.55 | [1.11-218.96] |
| Diagnosis by urine test, eGFR level, and kidney imaging | By urine test, eGFR level, and kidney imaging examination | Only by urine test | 0.01 | 34.80 | [2.30-527.49] | |
| Q5 | Occasional quantitative testing for albuminuria | Occasional check quantitative tests for albuminuria | No quantitative testing | 0.031 | 1.67 | [1.05-2.67] |
| Frequent quantitative testing for albuminuria | Frequent check of quantitative tests for albuminuria | No quantitative testing | 0.039 | 1.96 | [1.04-3.71] | |
| Q9 | Estimation of daily salt intake by 24-h urine collection | Yes | No | 0.001 | 0.04 | [0.006-0.23] |
| Q10 | Use of hemoglobin level to evaluate renal anemia | Yes | No | 0.017 | 4.52 | [1.31-15.66] |
| Use of transferrin saturation (TSAT) to evaluate renal anemia | Yes | No | 0.038 | 1.72 | [1.03-2.87] | |
| Q12 | Prescribes HIF-PH inhibitors at their own discretion | To prescribe HIF-PH inhibitors with my own discretion | Does not prescribe HIF-PH inhibitors | 0.003 | 2.10 | [1.28-3.45] |
| Q19 | Provides dietary therapy for patients with CKD | To provide dietary therapy at my clinics/hospitals | Does not provide dietary therapy | 0.003 | 2.56 | [1.37-4.76] |
| Q25 | Refers patients with evident proteinuria (> 0.5 g/gCr) to nephrologists | Yes | No | 0.017 | 0.57 | [0.36-0.90] |
| Refers patients with both proteinuria and hematuria to nephrologists | Yes | No | 0.002 | 2.03 | [1.29-3.19] | |
| Q27 | Consults nephrologists for proteinuria > 1.0 g/gCr or (2+) by qualitative test | >1.0g/gCr or (2+) by qualitative proteinuria test | > 0.15 g/gCr or (±) by qualitative test | 0.016 | 2.62 | [1.19-5.75] |